Full Press Release Details
New Data from Sagimet's Phase 2 FASCINATE-1 Clinical Trial Demonstrate TVB-2640's Positive Effect Across Patients with NASH in the U.S. and China.
SGMT
New Data from Sagimet's Phase 2 FASCINATE-1 Clinical Trial Demonstrate TVB-2640's Positive Effect Across Patients with NASH in the U.S. and China
Key Takeaway: New Data from Sagimet's Phase 2 FASCINATE-1 Clinical Trial Demonstrate TVB-2640's Positive Effect Across Patients with NASH in the U.S. and China